Furthermore, combination of SF3B1 inhibitor and αPDL1 showed excellent efficacy in mice ovarian cancer models, indicating a good clinical application prospect in immunotherapy in ovarian cancers. This evidence concerns the gene SF3B1 and ovarian carcinoma.